{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:14:11Z","timestamp":1793157251084,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"DOI":"10.1007\/s13679-023-00546-9","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T17:02:24Z","timestamp":1704301344000},"page":"132-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Phentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?"],"prefix":"10.1007","volume":"13","author":[{"given":"Kristina H.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Gudzune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamy D.","family":"Ard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"issue":"11","key":"546_CR1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989.","journal-title":"N Engl J Med"},{"issue":"3","key":"546_CR2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"key":"546_CR3","unstructured":"Zoler M. Wegovy U.S. Supply shortage strikes again. WebMD Health News. 2023 May 5 2023."},{"issue":"5","key":"546_CR4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-143-5-200509060-00013","volume":"143","author":"E Colman","year":"2005","unstructured":"Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med. 2005;143(5):380\u20135.","journal-title":"Ann Intern Med"},{"issue":"2","key":"546_CR5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","volume":"100","author":"CM Apovian","year":"2015","unstructured":"Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"546_CR6","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.metabol.2015.08.001","volume":"64","author":"D Patel","year":"2015","unstructured":"Patel D. Pharmacotherapy for the management of obesity. Metabolism. 2015;64(11):1376\u201385.","journal-title":"Metabolism"},{"issue":"2","key":"546_CR7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/pr.59.2.2","volume":"59","author":"GA Bray","year":"2007","unstructured":"Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007;59(2):151\u201384.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"546_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1385\/ENDO:29:1:49","volume":"29","author":"DL Nelson","year":"2006","unstructured":"Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2006;29(1):49\u201360.","journal-title":"Endocrine"},{"issue":"5","key":"546_CR9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.1992.68","volume":"51","author":"WM Introduction","year":"1992","unstructured":"Introduction WM. Clin Pharmacol Ther. 1992;51(5):581\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"546_CR10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.1992.76","volume":"51","author":"M Weintraub","year":"1992","unstructured":"Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51(5):642\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"546_CR11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.1992.69","volume":"51","author":"M Weintraub","year":"1992","unstructured":"Weintraub M, Sundaresan PR, Madan M, Schuster B, Balder A, Lasagna L, et al. Long-term weight control study I (weeks 0 to 34). Clin Pharmacol Ther. 1992;51(5):586\u201394.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"546_CR12","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/oby.22516","volume":"27","author":"S Murali","year":"2019","unstructured":"Murali S. Knowledge gaps in long-term phentermine use: making the case for maintenance. Obesity (Silver Spring). 2019;27(8):1219.","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"546_CR13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1210\/er.2017-00253","volume":"39","author":"GA Bray","year":"2018","unstructured":"Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: an Endocrine Society scientific statement. Endocr Rev. 2018;39(2):79\u2013132.","journal-title":"Endocr Rev"},{"key":"546_CR14","doi-asserted-by":"crossref","unstructured":"Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association Of Clinical Endocrinologists and American College Of Endocrinology Comprehensive Clinical Practice Guidelines for medical care of patients with obesity. Executive Summary Complete Guidelines available at https:\/\/www.aace.com\/publications\/guidelines. Endocr Pract. 2016;22(7):842\u201384.","DOI":"10.4158\/EP161356.ESGL"},{"key":"546_CR15","doi-asserted-by":"crossref","unstructured":"Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2013.","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"issue":"5","key":"546_CR16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","volume":"163","author":"E Grunvald","year":"2022","unstructured":"Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198\u2013225.","journal-title":"Gastroenterology"},{"issue":"31","key":"546_CR17","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875\u201391.","journal-title":"CMAJ"},{"key":"546_CR18","first-page":"1","volume":"360","author":"CM Hales","year":"2020","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018. NCHS Data Brief. 2020;360:1\u20138.","journal-title":"NCHS Data Brief"},{"key":"546_CR19","doi-asserted-by":"crossref","unstructured":"Saxon DR, Iwamoto SJ, Mettenbrink CJ, McCormick E, Arterburn D, Daley MF, et al. Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009\u20132015. Obesity (Silver Spring). 2019;27(12):1975\u201381.","DOI":"10.1002\/oby.22581"},{"key":"546_CR20","doi-asserted-by":"crossref","unstructured":"Almazan E, Schwartz JL, Gudzune KA. Use of medications associated with weight change among participants in the All of Us research programme. Clin Obes. 2023:e12609.","DOI":"10.1111\/cob.12609"},{"issue":"3","key":"546_CR21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11695-020-04987-2","volume":"31","author":"A Elangovan","year":"2021","unstructured":"Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity-trends using a population level national database. Obes Surg. 2021;31(3):1105\u201312.","journal-title":"Obes Surg"},{"issue":"4","key":"546_CR22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/oby.22430","volume":"27","author":"KH Lewis","year":"2019","unstructured":"Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring). 2019;27(4):591\u2013602.","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"546_CR23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"546_CR24","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"10","key":"546_CR25","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4158\/EP-2019-0081","volume":"25","author":"K Shibuya","year":"2019","unstructured":"Shibuya K, Ali KF, Ji X, Milinoivh A, Bauman J, Kattan MW, et al. The benefit of short-term weight loss with anti-obesity medications in real-world clinical practice. Endocr Pract. 2019;25(10):1022\u20138.","journal-title":"Endocr Pract"},{"issue":"1","key":"546_CR26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/phar.2048","volume":"38","author":"TR Grabarczyk","year":"2018","unstructured":"Grabarczyk TR. Observational comparative effectiveness of pharmaceutical treatments for obesity within the veterans health administration. Pharmacotherapy. 2018;38(1):19\u201328.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"546_CR27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/osp4.575","volume":"8","author":"BG Tchang","year":"2022","unstructured":"Tchang BG, Aras M, Wu A, Aronne LJ, Shukla AP. Long-term weight loss maintenance with obesity pharmacotherapy: a retrospective cohort study. Obes Sci Pract. 2022;8(3):320\u20137.","journal-title":"Obes Sci Pract"},{"key":"546_CR28","doi-asserted-by":"crossref","unstructured":"Cunningham JG, Szoka N, Tabone LE, Cox S, Aylward L, Abunnaja S. Preoperative and early adjuvant weight loss medications in bariatric surgery patients with body mass index over 60 or suboptimal initial response to surgery. Surg Obes Relat Dis: official journal of the American Society for Bariatric Surgery. 2023.","DOI":"10.1016\/j.soard.2023.01.021"},{"issue":"11","key":"546_CR29","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/oby.23548","volume":"30","author":"ML Griebeler","year":"2022","unstructured":"Griebeler ML, Butsch WS, Rodriguez P, Lomeli L, Kampert M, Makin V, et al. The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters. Obesity (Silver Spring). 2022;30(11):2194\u2013203.","journal-title":"Obesity (Silver Spring)"},{"key":"546_CR30","doi-asserted-by":"crossref","unstructured":"Rocha-Gonzalez HI, De la Cruz-Alvarez LE, Kammar-Garcia A, Canizales-Quinteros S, Huerta-Cruz JC, Barranco-Garduno LM, et al. Weight loss at first month and development of tolerance as possible predictors of 30 mg phentermine efficacy at 6 months. J Pers Med. 2021;11(12).","DOI":"10.3390\/jpm11121354"},{"issue":"11","key":"546_CR31","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/oby.21649","volume":"24","author":"CP Moldovan","year":"2016","unstructured":"Moldovan CP, Weldon AJ, Daher NS, Schneider LE, Bellinger DL, Berk LS, et al. Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings. Obesity (Silver Spring). 2016;24(11):2344\u201350.","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"546_CR32","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/oby.22503","volume":"27","author":"DD Thomas","year":"2019","unstructured":"Thomas DD, Waring ME, Ameli O, Reisman JI, Vimalananda VG. Patient characteristics associated with receipt of prescription weight-management medications among veterans participating in MOVE! Obesity (Silver Spring). 2019;27(7):1168\u201376.","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"546_CR33","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/oby.23120","volume":"29","author":"A Acosta","year":"2021","unstructured":"Acosta A, Camilleri M, Abu Dayyeh B, Calderon G, Gonzalez D, McRae A, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity (Silver Spring). 2021;29(4):662\u201371.","journal-title":"Obesity (Silver Spring)"},{"key":"546_CR34","unstructured":"U.S. Department of Health and Human Services FaDA, Center for drug evaluation and research. Guidance for industry: developing products for weight management. 2007."},{"issue":"8","key":"546_CR35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5414\/CP203943","volume":"59","author":"M Marquez-Cruz","year":"2021","unstructured":"Marquez-Cruz M, Kammar-Garcia A, Huerta-Cruz JC, Carrasco-Portugal MDC, Barranco-Garduno LM, Rodriguez-Silverio J, et al. Three- and six-month efficacy and safety of phentermine in a Mexican obese population. Int J Clin Pharmacol Ther. 2021;59(8):539\u201348.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"546_CR36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000524805","volume":"31","author":"E Perez-Cruz","year":"2022","unstructured":"Perez-Cruz E, Guevara-Cruz M, Ortiz-Gutierrez S, Luna-Camacho Y, Guzman-Aguilar R, Briceno-Saenz G, et al. Effect of phentermine on hepatic steatosis in bariatric surgery: a pilot study. Med Princ Pract. 2022;31(3):254\u201361.","journal-title":"Med Princ Pract"},{"issue":"5","key":"546_CR37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4082\/kjfm.2013.34.5.298","volume":"34","author":"HO Kim","year":"2013","unstructured":"Kim HO, Lee JA, Suh HW, Kim YS, Kim BS, Ahn ES, et al. Postmarketing surveillance study of the efficacy and safety of phentermine in patients with obesity. Korean J Fam Med. 2013;34(5):298\u2013306.","journal-title":"Korean J Fam Med"},{"key":"546_CR38","unstructured":"Lexicomp. Phentermine: drug information: Topic 9765 Version 211.0 2018 [Available from: Available at: https:\/\/www.uptodate.com\/contents\/phentermine-drug-information?search=phentermine&source=search_result&selectedTitle=1~13&usage_type=default&display_rank=1#F209150."},{"key":"546_CR39","unstructured":"Lexicomp. Phentermine and topiramate: drug information (Topic 85870 Version 263.0) 2023 [Available at: https:\/\/www-uptodate-com.wake.idm.oclc.org\/contents\/phentermine-and-topiramate-drug-information?search=qsymia:%20drug%20information&source=panel_search_result&selectedTitle=1~6&usage_type=panel&kp_tab=drug_general&display_rank=1#references]."},{"key":"546_CR40","unstructured":"Lexicomp. Semaglutide: drug information (Topic 115980 Version 217.0) 2023 [Available at: https:\/\/www-uptodate-com.wake.idm.oclc.org\/contents\/semaglutide-drug-information?source=auto_suggest&selectedTitle=1~1---1~4---semaglu&search=semaglutide]."},{"issue":"2","key":"546_CR41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/osp4.390","volume":"6","author":"M Lee","year":"2020","unstructured":"Lee M, Lauren BN, Zhan T, Choi J, Klebanoff M, Abu Dayyeh B, et al. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract. 2020;6(2):162\u201370.","journal-title":"Obes Sci Pract"},{"key":"546_CR42","doi-asserted-by":"crossref","unstructured":"Elhag W, El Ansari W, Abdulrazzaq S, Elsherif M, Mustafa I. Lorcaserin vs. Phentermine among non-surgical and surgical obese patients: anthropometric, glycemic, lipid, safety and cost outcomes. Ann Med Surg (Lond). 2019;45:75\u201381.","DOI":"10.1016\/j.amsu.2019.07.024"},{"issue":"5","key":"546_CR43","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41366-020-0544-4","volume":"44","author":"E Gorelik","year":"2020","unstructured":"Gorelik E, Gorelik B, Masarwa R, Perlman A, Hirsh-Raccah B, Matok I. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database. Int J Obes (Lond). 2020;44(5):1021\u20137.","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"546_CR44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/oby.21244","volume":"24","author":"EA Thomas","year":"2016","unstructured":"Thomas EA, McNair B, Bechtell JL, Ferland A, Cornier MA, Eckel RH. Greater hunger and less restraint predict weight loss success with phentermine treatment. Obesity (Silver Spring). 2016;24(1):37\u201343.","journal-title":"Obesity (Silver Spring)"},{"key":"546_CR45","doi-asserted-by":"crossref","unstructured":"Rothman RB, Elmer GI, Shippenberg TS, Rea W, Baumann MH. Phentermine and fenfluramine: preclinical studies in animal models of cocaine addiction. Ann N Y Acad Sci. 2006;844(1):59\u201374.","DOI":"10.1111\/j.1749-6632.1998.tb08222.x"},{"issue":"2","key":"546_CR46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ijo.2013.74","volume":"38","author":"EJ Hendricks","year":"2014","unstructured":"Hendricks EJ, Srisurapanont M, Schmidt SL, Haggard M, Souter S, Mitchell CL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes (Lond). 2014;38(2):292\u20138.","journal-title":"Int J Obes (Lond)"},{"key":"546_CR47","doi-asserted-by":"crossref","unstructured":"Force USPST, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US preventive services task force recommendation statement. JAMA. 2018;320(11):1163\u201371.","DOI":"10.1001\/jama.2018.13022"},{"issue":"10","key":"546_CR48","first-page":"759","volume":"172","author":"PG O'Malley","year":"2012","unstructured":"O\u2019Malley PG. What does off-label prescribing really mean? Arch Intern Med. 2012;172(10):759\u201360.","journal-title":"Arch Intern Med"},{"issue":"10","key":"546_CR49","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archinternmed.2012.340","volume":"172","author":"T Eguale","year":"2012","unstructured":"Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med. 2012;172(10):781\u20138.","journal-title":"Arch Intern Med"},{"issue":"9","key":"546_CR50","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","volume":"166","author":"DC Radley","year":"2006","unstructured":"Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021\u20136.","journal-title":"Arch Intern Med"},{"issue":"1","key":"546_CR51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jamainternmed.2015.6068","volume":"176","author":"CB Good","year":"2016","unstructured":"Good CB, Gellad WF. Off-label drug use and adverse drug events: turning up the heat on off-label prescribing. JAMA Intern Med. 2016;176(1):63\u20134.","journal-title":"JAMA Intern Med"},{"key":"546_CR52","unstructured":"Diversion Control Division UD. Controlled substance schedules 2023 [Available from: https:\/\/www.deadiversion.usdoj.gov\/schedules\/."},{"issue":"8","key":"546_CR53","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1310\/hpj4808-644","volume":"48","author":"M Gabay","year":"2013","unstructured":"Gabay M. Federal controlled substances act: controlled substances prescriptions. Hosp Pharm. 2013;48(8):644\u20135.","journal-title":"Hosp Pharm"},{"key":"546_CR54","unstructured":"Administration UFaD. Code of Federal Regulations Title 21: Chapter II, Part 1306, Prescriptions 2023 [Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=1306.22."},{"key":"546_CR55","unstructured":"Services UDoHaH. Prescribing controlled substances via telehealth 2023 [Available from: https:\/\/telehealth.hhs.gov\/providers\/telehealth-policy\/prescribing-controlled-substances-via-telehealth."},{"key":"546_CR56","unstructured":"Agency UDE. Dea\u2019s proposed telemedicine regulations: highlights for medical practitioners 2023 [Available from: https:\/\/www.dea.gov\/sites\/default\/files\/2023-03\/Telehealth_Practitioner_Narrative_312023.pdf."},{"key":"546_CR57","unstructured":"Pharmacy KBo. Frequently asked questions [Available from: https:\/\/pharmacy.ks.gov\/resources-consumer-info-2\/faq\/lists\/listsProvider10\/weight-loss\/can-a-controlled-substance-be-prescribed-to-treat-weight-loss."},{"key":"546_CR58","unstructured":"Commission OLS. Rule 4731\u201311\u201304: Controlled substances for the treatment of obesity 2023 [Available from: https:\/\/codes.ohio.gov\/ohio-administrative-code\/rule-4731-11-04."},{"issue":"1","key":"546_CR59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","volume":"311","author":"SZ Yanovski","year":"2014","unstructured":"Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74\u201386.","journal-title":"JAMA"},{"issue":"5588","key":"546_CR60","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","volume":"1","author":"JF Munro","year":"1968","unstructured":"Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J. 1968;1(5588):352\u20134.","journal-title":"Br Med J"},{"key":"546_CR61","doi-asserted-by":"crossref","unstructured":"Chai ST MN. SAT-LB022 Effects of intermittent versus continuous phentermine therapy on weight reduction and inflammatory markers in obese non-diabetic patients. J Endocr Soc. 2019;3(Suppl 1).","DOI":"10.1210\/js.2019-SAT-LB022"},{"key":"546_CR62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2021.01.002","volume":"93","author":"L Busetto","year":"2021","unstructured":"Busetto L, Bettini S, Makaronidis J, Roberts CA, Halford JCG, Batterham RL. Mechanisms of weight regain. Eur J Intern Med. 2021;93:3\u20137.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"546_CR63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"SR Smith","year":"2010","unstructured":"Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245\u201356.","journal-title":"N Engl J Med"},{"key":"546_CR64","doi-asserted-by":"crossref","unstructured":"Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023.","DOI":"10.1056\/NEJMoa2301972"},{"key":"546_CR65","unstructured":"Hudak J WG. How to reschedule marijuana, and why it\u2019s unlikely anytime soon 2015 [Available from: https:\/\/www.brookings.edu\/articles\/how-to-reschedule-marijuana-and-why-its-unlikely-anytime-soon\/."}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-023-00546-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-023-00546-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-023-00546-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T19:23:35Z","timestamp":1710271415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-023-00546-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["546"],"URL":"https:\/\/doi.org\/10.1007\/s13679-023-00546-9","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"2 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Lewis reports non-financial support from KVK Tech, and personal fees from American Board of Obesity Medicine, outside the submitted work; Dr. Gudzune reports grants and personal fees from Novo Nordisk, personal fees from Eli Lilly, personal fees from American Board of Obesity Medicine, and personal fees from Johns Hopkins ACG System, outside the submitted work; Dr. Ard reports personal fees and non-financial support from Nestle Healthcare Nutrition, grants and personal fees from Eli Lilly, grants from Epitomee, grants and personal fees from UnitedHealth Group, personal fees from Novo Nordisk, non-financial support from KVKTech, personal fees and non-financial support from Weight Watchers, personal fees from Regeneron, personal fees from Brightseed, grants and personal fees from Boehringer Ingelheim, and personal fees from Intuitive, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with animal subjects performed by any of the authors. This article does reference a previously published observational study in humans by Drs. Lewis and Ard and an ongoing clinical trial in humans on which all authors are Investigators. All clinical trials reported were overseen by Institutional Review Boards and included appropriate informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}